Gain Therapeutics to Participate at Upcoming Investor Conferences
Gain Therapeutics, Inc. (GANX)
Company Research
Source: GlobeNewswire
BETHESDA, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, interim Chief Executive Officer and current Chief Financial Officer of Gain, will participate in two upcoming investor conferences: 3rd Annual ROTH Healthcare Opportunities Conference on Wednesday, October 9. Gene Mack will participate in one-on-one meetings as well as the themed industry panel, “Emerging Frontiers in Neuroscience”. 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15 at 12pm ET. Gene Mack will participate in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group. To attend, sign up to become an M-Vest member and stay tuned for more updates. About Gain Therapeutics, Inc.Gain Therapeutics, Inc. is a clinical-sta
Show less
Read more
Impact Snapshot
Event Time:
GANX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GANX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GANX alerts
High impacting Gain Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GANX
News
- Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $7.00 price target on the stock.MarketBeat
- Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s DiseaseGlobeNewswire
- Gain Therapeutics To Present At Biotech Showcase 2025 [Yahoo! Finance]Yahoo! Finance
- Gain Therapeutics To Present At Biotech Showcase 2025GlobeNewswire
GANX
Earnings
- 11/14/24 - Beat
GANX
Sec Filings
- 12/23/24 - Form 8-K
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- GANX's page on the SEC website